LOS ANGELES, Aug. 30, 2023 (GLOBE NEWSWIRE) — (NASDAQ: RENB). Renovaro BioSciences congratulates GEDiCube on their joint effort to work to accelerate early diagnosis of cancer in clinical trials.
For more information: GEDiCube Press Release
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. All forward-looking statements are based on assumptions or judgments about future events and economic conditions that may or may not be correct or necessarily take place and that are by their nature, subject to significant risks, uncertainties, and contingencies. These forward-looking statements include but are not limited to, statements regarding the Renovaro-GEDi Cube transaction and Renovaro’s plans and expectations with respect to the potential transaction. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro BioSciences Inc. (NASDAQ: RENB) most recent Annual Report on Form 10-K filed with the SEC as well as whether Renovaro and GEDi Cube will enter into an agreement as to the definitive terms of the transaction; a condition to consummating the transaction may not be satisfied; Renovaro may be unable to obtain approval to list on the Nasdaq Capital Market the shares of Renovaro common stock expected to be issued pursuant to the transaction; the closing of the transaction might be delayed or not occur at all. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Biosciences, Inc. undertakes no obligation to revise or update this shareholder letter to reflect events or circumstances after the date hereof.
CONTACT: Investor Relations Contact: [email protected]